{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"89"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"213"},{"groupId":"OG005","value":"85"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"description":"Acute Graft-Versus-Host Disease (aGVHD) is a severe short-term complication created by infusion of donor cells into a foreign host. Determine the incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging.\n\nPatients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.","groups":[{"description":"Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant","id":"OG000","title":"PBSC: No TBI"},{"description":"Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant","id":"OG001","title":"Marrow : No TBI"},{"description":"Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant","id":"OG002","title":"UCB : No TBI"},{"description":"Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen","id":"OG003","title":"UCB : No TBI/Bu/Cy/ATG"},{"description":"Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant","id":"OG004","title":"PBSC"},{"description":"Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant","id":"OG005","title":"Marrow"},{"description":"Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant","id":"OG006","title":"Umbilical Cord Blood"},{"description":"Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)","id":"OG007","title":"Co-Enroll From MT0403"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Number of Participants With Acute Graft-versus-host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Participants"}